Amitkumar Mehta, MD
Advertisement
Articles by Amitkumar Mehta, MD
Amitkumar Mehta, MD, detailed encouraging data presented at the 63rd ASH Annual Meeting for treating mantle cell lymphoma.
Amitkumar Mehta, MD, discusses overall response rates from the CITADEL-205 study looking at parsaclisib for patients with relapsed/refractory mantle cell lymphoma.
Amitkumar Mehta, MD, discusses the role of parsaclisib and how it fits into the treatment landscape of relapsed/refractory mantle cell lymphoma.
In this interview we discuss the mechanisms of daratumumab, how it is currently used for the treatment of multiple myeloma, and how it might be used in the future.
Advertisement
Latest Updated Articles
ZUMA-7 Final Analysis: Key Efficacy and Safety FindingsPublished: December 19th 2025 | Updated:
Amitkumar Mehta, MD, on Results of CITADEL-205 Study Examining Parsaclisib in Relapsed/Refractory MCLPublished: January 31st 2022 | Updated:
- Amitkumar Mehta, MD, on Compelling Data From ASH in the Treatment of Lymphoma
Published: February 10th 2022 | Updated:
- Amitkumar Mehta, MD, Discusses the Role of Parsaclisib in Relapsed/Refractory MCL
Published: January 25th 2022 | Updated:
Amitkumar Mehta on the Immunomodulating Effects of Targeted Therapy for Multiple MyelomaPublished: December 15th 2016 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
Lu 177 Plus Immunotherapy Displays Responses in Prostate Cancer
2
Daratumumab Combo Yields Significantly Higher MRD Negativity in Multiple Myeloma
3
Ceralasertib Combo Misses OS End Point in Advanced NSCLC Trial
4
Achieving Accessible Cancer Care at Tennessee Oncology
5